Gastric or Esophagogastric Junction Adenocarcinoma Clinical Trials

4 clinical trials for Gastric or Esophagogastric Junction Adenocarcinoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma — RECRUITING · PHASE2
• LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study — RECRUITING · PHASE2
• Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma — RECRUITING · PHASE3
• PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer — ACTIVE_NOT_RECRUITING · PHASE3

Refine this search